Skip to main content

TPD52 (Tumor Protein D52)

  • Reference work entry
Encyclopedia of Signaling Molecules

Synonyms

CRHSP-28 (rat); CSPP28 (rabbit); hD52 (human); mD52 (mouse); N8 (human); PC-1 (human); PrLZ (human); R10 (quail); Tpd52 (mouse)

Historical Background and Overview

Mammalian TPD52 sequences were first reported in the mid-1990s, through a number of independent approaches. Two early reports identified TPD52 sequences through their increased expression in human cancer tissue or cell lines, relative to either nonmalignant tissues or fibroblast cell lines. Orthologous sequences from other species were identified as proteins phosphorylated in response to increased intracellular calcium, or as a retroviral target gene. Early reports also highlighted the existence of paralogous sequences in human and mouse, and TPD52 is now known to be part of a four-member mammalian gene family. While TPD52-like sequences are well conserved both within and between species, they show little homology with those of other proteins.

Human TPD52 isoforms are approximately 200 residues in length, and...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

References

  • Boutros R, Fanayan S, Shehata M, Byrne JA. The tumor protein D52 family: many pieces, many puzzles. Biochem Biophys Res Commun. 2004;325:1115–21.

    PubMed  CAS  Google Scholar 

  • Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, et al. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer. 2010;10:497.

    PubMed  Google Scholar 

  • Chew CS, Chen X, Zhang H, Berg EA, Zhang H. Calcium/calmodulin-dependent phosphorylation of tumor protein D52 on serine residue 136 may be mediated by CAMK2delta6. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1159–72.

    PubMed  CAS  Google Scholar 

  • Dutertre M, Gratadou L, Dardenne E, Germann S, Samaan S, Lidereau R, et al. Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer. Cancer Res. 2010;70:3760–70.

    PubMed  CAS  Google Scholar 

  • Kourtidis A, Jain R, Carkner RD, Eifert C, Brosnan MJ, Conklin DS. An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer Res. 2010;70:1783–92.

    PubMed  CAS  Google Scholar 

  • Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunol Immunother. 2009;58:1337–49.

    PubMed  CAS  Google Scholar 

  • Li L, Zhang D, Zhang L, Zhu G, Sun Y, Wu K, et al. PrLZ expression is associated with the progression of prostate cancer LNCaP cells. Mol Carcinog. 2009;48:432–40.

    PubMed  CAS  Google Scholar 

  • Mattison J, Kool J, Uren AG, de Ridder J, Wessels L, Jonkers J, et al. Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach. Cancer Res. 2010;70:883–95.

    PubMed  CAS  Google Scholar 

  • Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, et al. Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine. 2009;27:1825–33.

    PubMed  CAS  Google Scholar 

  • Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat. 2010;121:575–89.

    PubMed  CAS  Google Scholar 

  • Payton LA, Lewis JD, Byrne JA, Bright RK. Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunol Immunother. 2008;57:799–811.

    PubMed  CAS  Google Scholar 

  • Shehata M, Weidenhofer J, Thamotharampillai K, Hardy JR, Byrne JA. Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays. Crit Rev Oncog. 2008;14:33–55.

    PubMed  Google Scholar 

  • Thomas DD, Martin CL, Weng N, Byrne JA, Groblewski GE. Tumor protein D52 expression and Ca2+−dependent phosphorylation modulates lysosomal membrane protein trafficking to the plasma membrane. Am J Physiol Cell Physiol. 2010;298:C725–39.

    PubMed  CAS  Google Scholar 

  • Ummanni R, Teller S, Junker H, Zimmermann U, Venz S, Scharf C, et al. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS J. 2008;275:5703–13.

    PubMed  CAS  Google Scholar 

  • Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, Ivey RG, et al. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res. 2007;6:3962–75.

    PubMed  CAS  Google Scholar 

  • Zhao P, Zhong W, Ying X, Yao B, Yuan Z, Fu J, et al. Comparative proteomic analysis of anti-benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide-transformed and normal human bronchial epithelial G0/G1 cells. Chem Biol Interact. 2010;186:166–73.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jennifer Anne Byrne .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this entry

Cite this entry

Della-Franca, A., Chen, Y., Byrne, J.A. (2012). TPD52 (Tumor Protein D52). In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0461-4_555

Download citation

Publish with us

Policies and ethics